Open AccessSpecies Difference of (2R,4R)-2-(o-Hydroxyphenyi)-3-(3-Mercaptopropionyl)-4-Thiazolidinecarboxylic Acid (SA446) in Inhibition of Angiotensin Converting Enzyme
Author(s) -
Katsuhiko Nakata,
Terumichi Iwatani,
Masato Horiuchi,
Hirokazu Kito,
Hideyasu Yamauchi,
Tadashi Iso
Publication year - 1986
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.40.367
Subject(s) - in vivo , captopril , in vitro , cats , pharmacology , chemistry , enzyme , angiotensin converting enzyme , renin–angiotensin system , significant difference , angiotensin ii , endocrinology , medicine , biochemistry , biology , blood pressure , receptor , microbiology and biotechnology
A marked species difference was observed both in vitro and in vivo in the activity of SA446, an orally active inhibitor of angiotensin converting enzyme (ACE), as compared with that of captopril in five different animal species. The activity of SA446 in vitro in inhibiting plasma ACE correlated with the activity in vivo as determined by inhibition of the pressor response to angiotensin I (AI). SA446 was more potent as an inhibitor of AI response in dogs, cats and rabbits than in guinea pigs and rats. Furthermore, ACE activity in whole blood in vivo was inhibited by SA446, and the activity of SA446 was also more potent in dogs than in rats. The concentration of SA446 in the ultrafiltrate of blood (free form) was significantly higher in dogs than in rats, while no difference was observed in level of SA446 in the whole blood (free and protein-bound form) between these two species after intravenous injection. The binding rate of SA446 to plasma protein of rats in vitro was more than twice as high as that of dogs. These results suggest that the difference in the protein binding rate of SA446 is reflected in ultrafiltrate level and is one of the important components in defining the species difference in SA446 action.